Brand Name | Status | Last Update |
---|---|---|
luspatercept | Biologic Licensing Application | 2019-11-18 |
reblozyl | Biologic Licensing Application | 2024-05-17 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
anemia | EFO_0004272 | D000740 | D64.9 |
Expiration | Code | ||
---|---|---|---|
luspatercept, Reblozyl, Celgene Corporation, a Bristol-Myers Squibb Company | |||
2030-08-28 | Orphan excl. |
Code | Description |
---|---|
J0896 | Injection, luspatercept-aamt, 0.25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | 2 | 1 | 3 | 8 |
Preleukemia | D011289 | — | — | — | 1 | 2 | 1 | 3 | 7 |
Anemia | D000740 | EFO_0004272 | D64.9 | — | 3 | 1 | 1 | — | 5 |
Thalassemia | D013789 | EFO_1001996 | D56 | — | 2 | — | 1 | 2 | 5 |
Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | — | 1 | 2 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Myeloproliferative disorders | D009196 | — | D47.1 | — | 1 | — | — | — | 1 |
Neutropenia | D009503 | — | D70 | — | 1 | — | — | — | 1 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | — | — | — | 1 |
Leukopenia | D007970 | EFO_0004233 | D72.819 | — | 1 | — | — | — | 1 |
Clonal hematopoiesis | D000082182 | — | — | — | 1 | — | — | — | 1 |
Cytopenia | D000095542 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Luspatercept |
INN | luspatercept |
Description | Luspatercept |
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1373715-00-4 |
RxCUI | 2262544 |
ChEMBL ID | CHEMBL3039545 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB12281 |
UNII ID | AQK7UBA1LS (ChemIDplus, GSRS) |